Anixa Biosciences Inc Contracts & Agreements

Joint Development and Option Agreement, dated May 3, 2024, between the Company and The Cleveland Clinic Foundation. (Certain information has been redacted in the marked portions... (Filed With SEC on June 4, 2024)

Amendment to Exclusive License Agreement between the Company and The Cleveland Clinic Foundation (Filed With SEC on January 16, 2024)

Amendment No. 1 to Exclusive License Agreement between The Cleveland Clinic Foundation and Anixa Biosciences, Inc. (Certain information has been redacted in the marked portions of... (Filed With SEC on September 9, 2022)

Form of Warrant issued to Acorn Management Partners LLC (Filed With SEC on January 4, 2022)

Amended and Restated Collaboration Agreement, dated November 1, 2021, between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc (Filed With SEC on January 4, 2022)

Assignment Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH (Filed With SEC on June 10, 2021)

Amendment 2 to the Collaboration Agreement between the Company and MolGenie GmbH. (Certain information has been redacted in the marked portions of the exhibit.) (Filed With SEC on June 10, 2021)

Amended and Restated Underwriting Agreement, dated March 22, 2021, between Anixa Biosciences, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on March 24, 2021)

Form of Underwriter Warrants (Filed With SEC on March 24, 2021)

Amendment to License Agreement between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Certain information has been redacted in the marked portions... (Filed With SEC on March 11, 2021)

Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation. (Certain information has been redacted in the marked... (Filed With SEC on March 11, 2021)

Form of Warrant issued to Acorn Management Partners LLC (Filed With SEC on January 7, 2021)

Amendment 2 to the Collaboration Agreement between Certainty Therapeutics, Inc. and H. Lee Moffitt Cancer Center and Research Institute, Inc. (.) (Certain information has been... (Filed With SEC on January 7, 2021)

Amendement to Collaboration Agreement between the Company and OntoChem GmbH (Filed With SEC on January 7, 2021)

Exclusive License Agreement, dated October 20, 2020, between the Company and The Cleveland Clinic Foundation. (.) (Certain information has been redacted in the marked portions of... (Filed With SEC on January 7, 2021)

Redactions with respect to certain portions hereof denoted with *** COLLABORATION AGREEMENT (Filed With SEC on June 9, 2020)

AMENDMENT 1 TO THE COLLABORATION AGREEMENT BETWEEN CERTAINTY THERAPEUTICS, INC. AND H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (Filed With SEC on September 6, 2019)

Redactions with respect to certain portions hereof denoted with “***” EXCLUSIVE LICENSE AGREEMENT between THE CLEVELAND CLINIC FOUNDATION and ANIXA BIOSCIENCES, INC. dated as... (Filed With SEC on September 6, 2019)

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement March 27, 2018 B. Riley FBR, Inc. 299 Park Avenue, 7th Floor New York, NY, 10171 (Filed With SEC on March 27, 2018)

Confidential Treatment Requested by ITUS Corporation, IRS Employer Identification No. 11 ###-###-#### ***CONFIDENTIAL TREATMENT REQUESTED*** (Filed With SEC on January 9, 2018)

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement (Filed With SEC on November 17, 2017)

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement (Filed With SEC on September 29, 2017)

PLACEMENT AGENCY AGREEMENT (Filed With SEC on May 17, 2017)

DEALER-MANAGER AGREEMENT (Filed With SEC on March 8, 2017)

Warrant to Purchase 500,000 Shares ITUS CORPORATION COMMON STOCK PURCHASE WARRANT (Filed With SEC on December 7, 2016)

LETTER AGREEMENT (Filed With SEC on December 7, 2016)

ITUS CORPORATION 12% Secured Debenture Due November 11, 2017 (Filed With SEC on December 7, 2016)

ITUS CORPORATION Common Stock (par value $0.01 per share) At Market Issuance Sales Agreement (Filed With SEC on October 2, 2015)

SETTLEMENT AGREEMENT (Filed With SEC on January 5, 2015)

PATENT ASSIGNMENT AGREEMENT (Filed With SEC on January 5, 2015)

DEBT CONVERSION AGREEMENT (Filed With SEC on December 8, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on December 8, 2014)

TERMINATION AGREEMENT (Filed With SEC on December 8, 2014)

Warrant to Purchase 9,249,472 Shares ITUS CORPORATION COMMON STOCK PURCHASE WARRANT (Filed With SEC on December 8, 2014)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on July 15, 2014)

EXHIBIT 4.1 (Filed With SEC on July 15, 2014)

EXHIBIT 10.1 EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on September 14, 2011)

EXHIBIT 10.2 LICENSE AGREEMENT (Filed With SEC on September 14, 2011)

AMENDMENT NO. 1 TO THE COPYTELE, INC. 2010 SHARE INCENTIVE PLAN (Filed With SEC on July 7, 2011)

[COPYTELE, INC. LETTERHEAD] (Filed With SEC on February 14, 2011)

Warrant No. ___Expiration Date: February 7, 2016 Warrant to Purchase _____________ Shares (Filed With SEC on February 10, 2011)

Warrant No. ___Expiration Date: February 7, 2016 Warrant to Purchase ______________ Shares (Filed With SEC on February 10, 2011)

_____________________________________________ (Filed With SEC on February 10, 2011)

Exhibit 10.21 [COPYTELE, INC. LETTERHEAD] (Filed With SEC on September 14, 2010)

Exhibit 10.22 [COPYTELE, INC. LETTERHEAD] (Filed With SEC on September 14, 2010)

COPYTELE, INC. 2010 SHARE INCENTIVE PLAN (Filed With SEC on July 20, 2010)

COPYTELE, INC. 2010 SHARE INCENTIVE PLAN STOCK AWARD AGREEMENT (Filed With SEC on July 20, 2010)

Amendment No. 6 to the CopyTele, Inc. 2003 Share Incentive Plan Amended by the Companys Board of Directors on July 15, 2010 (Filed With SEC on July 20, 2010)

AMENDMENT OF OPTION AGREEMENTS (Filed With SEC on July 20, 2010)

Exhibit 10.21 [COPYTELE, INC. LETTERHEAD] (Filed With SEC on June 14, 2010)

Exhibit 10.22 [COPYTELE, INC. LETTERHEAD] (Filed With SEC on June 14, 2010)

COMMONSTOCK PURCHASE WARRANT THE SECURITIES REPRESENTED BY THIS CERTIFICATE, THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF, AND ANY INTEREST THEREIN MAY NOT BE OFFERED OR SOLD... (Filed With SEC on January 29, 2010)

Category

Industry

Companies

Contracts

Anixa Biosciences Inc Contracts & Agreements